Detailed price information for Editas Medicine (EDIT-Q) from The Globe and Mail including charting and trades.

Dr Giovanni Pietrogrande and Dr Tahmina Tabassum developed their new fusion protein at UQ's Australian Institute for ...

Advanced non-viral gene delivery systems are expanding the range of indications and therapy modalities possible for the new generation of genetic medicines.

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first ...

IDT played a pivotal role in manufacturing the personalized gene editing therapy given to baby KJ Muldoon to treat his rare ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...

Intellia Therapeutics (NTLA) is a clinical-stage biotech firm working on CRISPR-based treatments that try to edit genes ...

CRISPR-Cas9 is an RNA-guided DNA-cutting enzyme system that allows researchers to modify the genetic code of virtually any organism with a precision, speed, and affordability previously unattainable.

Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...